Summary

• Amsterdam-based OurMind has raised €2.1m in a round led by 4impact capital, with general practitioners and medical specialists also investing.
• Its platform started with AI-generated consultation notes and is expanding into preparation, administrative support, patient communication, and protocol queries.
• The company sits at the intersection of health tech, workforce pressure, clinical safety, documentation quality, and public-service capacity in European healthcare.

OurMind has raised €2.1m to expand its AI platform for healthcare administration, targeting the time clinicians lose to preparing, documenting, summarising, and processing patient interactions.

The Amsterdam-based company’s round was led by 4impact capital, with a group of general practitioners and medical specialists also contributing. The funding will be used to scale the platform and meet demand from hospitals, as Dutch healthcare organisations look for ways to handle rising workloads without relying only on extra staff.

OurMind was founded in 2024 by Paul Koning, Marco Ferraz, and Fredrik Gustafsson. Koning, a former orthopaedic surgeon, gives the company a clinical-founder profile in a market where software built without frontline workflow knowledge often struggles to move beyond pilot projects.

The company began with Notes, an AI product that converts conversations during consultations into medical documentation. Its broader platform now covers clinical notes, letters, summaries, consultation preparation, protocol questions, and patient communication. OurMind’s website says the system supports clinicians across general practices, hospital wards, cardiology, psychology, telephone consultations, and other care settings.

More than 300 general practices and 14 hospitals use the platform, according to 4impact. OurMind’s materials include examples such as WZA Cardiology using its assistant for routine inbound patient questions, St Jansdal doctors using Notes during consultations, and Saxenburgh hospital rolling the platform out across multiple specialisms after a pilot.

The funding arrives against a difficult workforce backdrop in Dutch healthcare. A quarter of young doctors report burnout symptoms, according to research cited by 4impact, while one in seven workers in the Netherlands currently works in healthcare. The Scientific Council for Government Policy has warned that the figure could rise to one in four by 2040 if demand continues on its present path.

Those pressures explain why administrative AI has become one of the more plausible areas of healthcare automation. Clinical labour is scarce, expensive, and politically sensitive, while documentation has expanded through regulation, billing, quality reporting, electronic health records, and defensive medicine. Doctors can spend hours outside patient contact preparing consultations, writing notes, completing letters, and handling routine communication.

Ambient documentation and clinical-assistant tools promise relief, but the category carries obvious risk. Medical notes are not ordinary meeting summaries. They can influence diagnosis, treatment, referrals, reimbursement, legal accountability, and continuity of care. If AI misses nuance, inserts errors, or compresses uncertainty too aggressively, clinicians may save time in the short term while pushing risk into later decisions.

OurMind’s emphasis on clinician control is therefore central to whether the product can be trusted. The platform drafts reports and supports administrative work, but the clinical professional remains responsible for the record and the decision. That division requires careful interface design, audit trails, integration with electronic health record systems, and enough transparency for doctors to understand what has been captured, omitted, or inferred.

The market is also shaped by data protection and procurement constraints. Healthcare AI systems process sensitive personal data, and European deployments must operate within GDPR, medical confidentiality rules, hospital governance, procurement frameworks, and national health-system expectations. Hospitals will need assurance over where data is processed, how models are trained or constrained, how errors are logged, and whether the software can integrate without creating additional work for IT teams.

OurMind’s investor mix gives the company a useful signal. A round backed not only by an impact investor but also by practising doctors suggests the product is addressing a recognised workflow problem, rather than a speculative AI use case pushed from outside the health system. That does not guarantee clinical value, but it gives the adoption path more credibility than a general-purpose AI tool repackaged for medicine.

The strongest commercial opening may be in narrow, measurable workflows. Consultation notes, referral letters, and routine patient communication are specific enough to review, audit, and improve. Wider claims about an AI layer across the hospital will require more evidence, especially where systems touch triage, diagnosis, care coordination, or patient-facing advice.

Healthcare systems across Europe are searching for capacity that does not depend solely on training more clinicians or stretching existing staff further. OurMind’s funding is small by AI market standards, but the operational problem is large. If the company can reduce paperwork without weakening clinical quality, it will sit in one of the few healthcare AI categories where the productivity case is direct, measurable, and tied to pressure felt across public and private care settings.